LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, a leading provider of injectable medicines, announced today it has launched the diagnostic pharmaceutical agent, Sincalide for Injection, an authorized generic for Bracco Diagnostics Inc.’s Kinevac® (Sincalide for Injection) product. The new product broadens Fresenius Kabi’s radiology portfolio and is available immediately in the United States.
Kinevac® (Sincalide):Teva Pharmaceuticals International GmbH et al v. Slayback Pharma Limited Liability Company
KINEVAC® (Sincalide): BRACCO DIAGNOSTICS INC., v.MAIA PHARMACEUTICALS, INC., )